Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that five new drugs for generalized anxiety disorder (GAD) will arrive to market by 2008. Those expected to gain marketing approval for GAD by 2008 include Pfizer's pregabalin, Lundbeck/Forest Laboratories' escitalopram, Indevus Pharmaceutical's pagoclone, Dov Pharmaceuticals/Elan's ocinaplon, and Eli Lilly's LY-354740 pro-drug. In contrast, in 2002 only two drugs--GlaxoSmithKline's Paxil/Seroxat and Wyeth's Effexor XR--were specifically approved for treatment of GAD, according to a new Pharmacor study entitled Generalized Anxiety Disorder.
The study also found that the GAD drug market is constrained by the fact that 50% of patients suffer from a comorbid psychiatric condition that masks the anxiety.
"We estimate that no more than 40-50% of GAD suffers will ever be correctly diagnosed because at least half of the patients who consult a physician will be diagnosed with a comorbid condition, such as major depression, as the primary disorder," said Tricia Nagle, analyst at Decision Resources. "Moreover, there will always be a significant percentage of GAD suffers who will never seek treatment for their condition because they consider it to be merely a part of their personality that does not require drug treatment."
About Generalized Anxiety Disorder
GAD is one of the most prevalent anxiety disorders and affects 4% of the general population. Despite its debilitating nature, GAD is frequently undiagnosed, either because it is masked by one of many common psychiatric comorbidities that physicians identify more readily (e.g., major depression, panic disorder) or simply because people with GAD do not seek treatment. Nearly 15 million people in the seven major pharmaceutical markets (United States, United Kingdom, Japan, Germany, Spain, Italy, and France) suffered from GAD in 2002, but diagnosis rates remain low: up to 65% of afflicted persons in the major markets were undiagnosed in 2002. However, diagnosis rates have increased over the past decade as a result of greater social acceptance of psychiatric disorders, fostered in part by campaigns conducted by drug manufacturers and professional societies to raise awareness of these conditions.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Generalized Anxiety Disorder is a Psychiatric Disorders study.
About Decision Resources
Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.,
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.decisionresources.com/